Comparison of Survival Outcomes with or Without Para-aortic Lymphadenectomy in Surgical Patients with Stage IB1-IIA2 Cervical Cancer in China from 2004-2016

Chunlin Chen (ccl1@smu.edu.cn)
Southern Medical University

Hui Duan
Southern Medical University

Wenling Zhang
Southern Medical University

Hongwei Zhao
Shanxi Provincial Cancer Hospital

Li Wang
Affiliated Cancer Hospital of zhengzhou university

Shan Kang
Fourth Hospital Hebei Medical University

Lihong Lin
The Anyang Tumor Hospital of Henan Province

Weidong Zhao
Anhui Cancer Hospital

Yan Ni
Yuncheng Central Hospital

Donglin Li
Guizhou people's Hospital

Jiaming Chen
Southern Medical University

Huijian Fan
Southern Medical University

Xiaolin Chen
Southern Medical University

Xiaonong Bin
Guangzhou Medical University

Jinghe Lang
Peking Union Medical College Hospital, Peking Union Medical College
Ping Liu
Southern Medical University

Research Article

Keywords: cervical cancer, para-aortic lymphadenectomy, metastasis, survival outcomes, pelvic lymph node

DOI: https://doi.org/10.21203/rs.3.rs-506335/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Current opinions on whether surgical patients with cervical cancer should undergo para-aortic lymphadenectomy at the same time are inconsistent. The present study examined differences in survival outcomes with or without para-aortic lymphadenectomy in surgical patients with stage IB1-IIA2 cervical cancer.

Methods: We retrospectively compared the survival outcomes of 8802 cervical cancer patients with stage IB1-IIA2 (FIGO 2009) from 37 hospitals in mainland China, who underwent abdominal radical hysterectomy + pelvic lymphadenectomy (n=8445) or abdominal radical hysterectomy + pelvic lymphadenectomy + para-aortic lymphadenectomy (n=357).

Results: Among the 8802 patients with stage IB1-IIA2 cervical cancer, 1618 (18.38%) patients had postoperative pelvic lymph node metastasis, and 37 (10.36%) patients had para-aortic lymph node metastasis. When pelvic lymph node metastasized, the para-aortic lymph node simultaneous metastasis rate was 30.00% (36/120). The risk of isolated para-aortic lymph node metastasis was 0.42% (1/237). There were no significant differences in the survival outcomes between the para-aortic lymph node unresected and resected groups. No differences in the survival outcomes were found before or after matching between the two groups regardless of pelvic lymph node negativity/positivity.

Conclusion: Para-aortic lymphadenectomy did not improve 5-year survival outcomes in surgical patients with stage IB1-IIA2 cervical cancer. Therefore, when pelvic lymph node metastasis is negative, the risk of isolated para-aortic lymph node metastasis is very low, and para-aortic lymphadenectomy is not recommended. When pelvic lymph node metastasis is positive, para-aortic lymphadenectomy should be carefully selected because of the high risk of this procedure.

Introduction

Cervical cancer ranks fourth for incidence and mortality in females[1]. Therefore, it is of great importance to optimize individual treatments for cervical cancer. The National Comprehensive Cancer Network (NCCN) guidelines[2] state that the main surgical procedure for stage IB1/IIB1 cervical cancer is radical hysterectomy (RH) + pelvic lymphadenectomy (PL) (category 1), with or without para-aortic lymphadenectomy (PAL) (category 2B for PAL); and the second choice is RH + PL ± PAL for stage IB2/IIB2 cervical cancer (category 2B). Using the National Cancer Database, Del Carmen et al.[3] included 3212 surgical patients with stage IA2-IB2 cervical cancer and found no statistically significant difference in the 3-year survival rates between pelvic lymph node (PLN) + para-aortic lymph node (PALN) resection and PLN resection alone (p=0.69). Tsuruga et al.[4] showed that PAL did not positively impact the 5-year survival rate in 308 patients. Ayhan A et al.[5] reported the same results. Hackett TE et al.[6] suggested that surgical patients with cervical cancer stage IA2-IIB undergo PAL when PLN or PALN is suspected of metastasis.
Current opinions on whether surgical patients with stage IB1-IIA2 cervical cancer should undergo PAL at the same time are inconsistent, especially when the PLN are negative or positive. Tsuruga et al.\cite{4} and Finan MA et al.\cite{7} showed that a PALN non-resection group had lower surgical complications than a PALN resection group.

Based on the clinical diagnosis and treatment for cervical cancer in China (Four C) database, our purpose is to assess the survival outcomes with or without PAL in surgical patients with stage IB1-IIA2 cervical cancer.

**Methods**

1. **Establishment of the China Cervical Cancer Clinical Database**

This multicenter retrospective study was approved by the Ethics Committee of the Nanfang Hospital of Southern Medical University (No. NFEC-2017-135) and is registered at the International Clinical Trials Registry Platform Search Port (https://apps.who.int/trialsearch/) under clinical trial registration number CHICTR1800017778. This retrospective cohort study was conducted following the ethical standards adopted in the 1964 Declaration of Helsinki. The four C database was developed in collaboration with 37 hospitals in mainland China and contains 46,313 cases of cervical cancer patients who received inpatient treatment from 2004 to 2016.

1.1 **Data collection**

Uniformly trained gynecologists collected the data using standardized data collection and quality control procedures. Patients’ medical records and pathology and examination reports were consulted, and data, including demographics, clinicopathologic features and treatment, were collected, with specific reference to our published studies\cite{8, 9}. Among these parameters, clinical staging was revised according to the 2009 International Federation of Gynecology and Obstetrics (FIGO) staging standard\cite{10}. After data collection was completed, two gynecologists performed independent information verification to ensure the accuracy and integrated missing or incomplete data in the supplementary medical records, such as the patient's case records and pathology and examination reports.

1.2 **Follow-up**

Because this study was a multicenter retrospective study, trained follow-up personnel at each participating unit performed follow-up during 1-2 telephone calls. All phone numbers were called uniformly based on the medical record management center. The follow-up content included survival status, relapse and complications. For patients whose phone number was incorrect or could not be
reached, we used the last visit or report time as the survival time and extracted tumor recurrence from outpatient medical record-related information from the hospital's outpatient medical records, picture archiving and communication system (PACS) and clinical laboratory information system.

1.3 Double data input

Two specially trained gynecologists input the same data into EpiData software and reviewed the doubtful information to ensure accuracy.

1.4 Data storage

After collecting all case information and follow-up data and completing double-input verification, the data were aggregated and managed by a professional to establish a unified database.

2. Inclusion and exclusion criteria

The following inclusion criteria were used: (1) FIGO stage IB1-IIA2 (FIGO 2009 staging system); (2) age ≥18 years old; (3) biopsy or postoperative pathology confirmed as squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma; (4) no neoadjuvant chemotherapy or radiotherapy before surgery; (5) Q-M type B or type C abdominal radical hysterectomy (ARH) + PL ± PAL; and (6) complete postoperative pathological data. The following exclusion criteria were used: (1) pregnancy with cervical cancer; (2) cervical stump cancer; (3) combined with other malignancies; (4) follow-up was lost; and (5) did not meet the inclusion criteria. The scope of PAL includes PALN biopsy, low abdominal PALN resection, and high abdominal PALN resection.

3. Case-control matching

The factors included in the multivariate analysis were age, FIGO stage, whether a PALN was resected, histological type, vaginal margin, parametrial infiltration, tumor diameter, deep stromal invasion, lymphovascular invasion (LVSI), and whether postoperative adjuvant treatment was standard. Whether postoperative adjuvant treatment was standard was based on pathological factors according to the guidelines for treatment\[11, 12\]: one or more postoperative pathological high-risk factors (positive lymph nodes, parametrial infiltration or positive margins): external-beam radiation therapy + platinum-containing concurrent chemotherapy (level of evidence 1) ± vaginal brachytherapy; and intermediate-risk factors (tumor size, deep stromal invasion, LVSI) according to the "Sedlis criteria" (level of evidence 1): external-beam radiation therapy ± concurrent platinum-containing chemotherapy (simultaneous chemotherapy evidence level 2B).
Because the clinicopathological data of the PALN unresected and resected groups may have differed, we used propensity score matching (PSM) / case-control matching to balance the factors that were different between the two groups to ensure that the groups were comparable.

4. Outcome evaluation

The main observation outcomes were the 5-year overall survival (OS) rate and the 5-year disease-free survival (DFS) rate between the PALN unresected and resected groups of the overall and different PLN metastasis states. OS was defined as the date of diagnosis to death from any cause or the last effective follow-up. DFS was defined as the date of diagnosis to death, relapse or the last effective follow-up.

5. Statistical analysis

Data analysis was performed using SPSS statistical software (version 23.0, SPSS Inc., Chicago, IL, USA). Two independent sample \( t \) tests were used for continuous variables, and the \( \chi^2 \) test or nonparametric test was used for categorical variables or grade variables. The log-rank test in the Kaplan-Meier (KM) method was used to compare the 5-year survival outcomes (OS, DFS) of the two groups. The Cox proportional hazards regression model was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for the multivariate analysis. \( P < 0.05 \) was considered statistically significant. Statistical experts reviewed all statistical methods and statistical processes in this study.

Results

According to the inclusion and exclusion criteria, we ultimately selected 8802 patients with stage IB1-IIA2 cervical cancer who underwent abdominal surgery, and the median follow-up time was 41 months. Among the 8802 patients, 1618 (18.38%) patients had postoperative PLN metastasis, and 357 (4.06%) patients had PAL. The PALN metastasis rate was 10.36% (37/357). When PLN metastasized, the PALN simultaneous metastasis rate was 30.00% (36/120). The risk of isolated PALN metastasis was 0.42% (1/237). Figure 1 shows the screening process used in this study.

1. Overall analysis (see Table 1 and Fig. 2)
| Variables                  | unmatched | matched | matched |
|----------------------------|-----------|---------|---------|
|                            | unmatche | PALN    | PALN    | P-value | unmatche | PALN    | PALN    | P-value |
|                            | PALN     |PALN Resected|PALN Resected|         |unresected|Resected|unresected|Resected|         |
|                            | (n = 8445,%) | (n = 357,%) | (n = 1385,%) |         | (n = 353,%) | (n = 1385,%) |         |         |
| Age(years)                 | 48.31 ± 9.737 | 47.77 ± 9.436 | 0.310 | 48.48 ± 9.603 | 47.75 ± 9.353 | 0.202 |
| FIGO stage                 | 0.072 | 0.925 |
| IB1                        | 4779(56.6%) | 201(56.3%) | 740(53.4%) | 200(56.7%) |
| IB2                        | 885(10.5%) | 52(14.6%) | 209(15.1%) | 50(14.2%) |
| IIA1                       | 1898(22.5%) | 71(19.9%) | 308(22.2%) | 71(20.1%) |
| IIA2                       | 613(7.3%) | 28(7.8%) | 105(7.6%) | 27(7.6%) |
| IB                         | 123(1.5%) | 2(0.6%) | 9(0.6%) | 2(0.6%) |
| IIA                        | 147(1.7%) | 3(0.8%) | 14(1.0%) | 3(0.8%) |
| Tumor size                 | 0.018 | 0.886 |
| ≤ 4cm                      | 6677(79.1%) | 272(76.2%) | 1048(75.7%) | 271(76.8%) |
| > 4cm                      | 1498(17.7%) | 80(22.4%) | 314(22.7%) | 77(21.8%) |
| Unknown                    | 270(3.2%) | 5(1.4%) | 23(1.7%) | 5(1.4%) |
| Histological type          | < 0.001 | 0.498 |
| SCC                        | 7587(89.8%) | 289(81.0%) | 1154(83.3%) | 287(81.3%) |
| AC                         | 656(7.8%) | 52(14.6%) | 168(12.1%) | 51(14.4%) |
| SAC                        | 202(2.4%) | 16(4.5%) | 63(4.5%) | 15(4.2%) |
| Parametrical               | < 0.001 | 0.634 |
| Negative                   | 8307(98.4%) | 338(94.7%) | 1330(96.0%) | 337(95.5%) |
| Positive                   | 138(1.6%) | 19(5.3%) | 55(4.0%) | 16(4.5%) |

*PALN* para-aortic lymph node, *PLN* pelvic lymph node, *FIGO* International Federation of Gynecology and Obstetrics, *SCC* squamous cell carcinoma, *AC* adenocarcinoma, *SAC* adenosquamous carcinoma, *LVS I* lymphatic vessel space, *POAT* postoperative adjuvant treatment
| Variables                      | unmatched       | matched       | P-value | matched       | P-value |
|-------------------------------|-----------------|---------------|---------|---------------|---------|
|                               | PALN unresected  | PALN Resected |         | PALN unresected|         |
|                               | (n = 8445,%)    | (n = 357,%)   |         | (n = 1385,%)  |         |
| **Vaginal margin**            |                 |               |         |               |         |
| Negative                      | 8250 (97.7%)    | 341 (95.5%)   | 0.009   | 1343 (97.0%)  | 0.375   |
| Positive                      | 195 (2.3%)      | 16 (4.5%)     |         | 42 (3.0%)     |         |
| **LVSI**                      |                 |               | < 0.001 |               | 0.979   |
| Negative                      | 6887 (81.6%)    | 262 (73.4%)   |         | 1025 (74.0%)  |         |
| Positive                      | 1558 (18.4%)    | 95 (26.6%)    |         | 360 (26.0%)   |         |
| **Cervical invasion**         |                 |               | 0.001   |               | 0.898   |
| ≤ 1/2                         | 3289 (38.9%)    | 108 (30.3%)   |         | 415 (30.0%)   |         |
| > 1/2                         | 4598 (54.4%)    | 230 (64.4%)   |         | 902 (65.1%)   |         |
| Unknown                       | 558 (6.6%)      | 19 (5.3%)     |         | 68 (4.9%)     |         |
| **POAT**                      |                 |               | 0.375   |               | 0.903   |
| standard                      | 4619 (54.7%)    | 207 (58.0%)   |         | 811 (58.6%)   |         |
| inadequate                    | 736 (8.7%)      | 35 (9.8%)     |         | 145 (10.5%)   |         |
| over                          | 2927 (34.7%)    | 110 (30.8%)   |         | 407 (29.4%)   |         |
| Unknown                       | 163 (1.9%)      | 5 (1.4%)      |         | 22 (1.6%)     |         |
| **PLN metastasis**            |                 |               | < 0.001 |               | 0.462   |
| Negative                      | 6947 (82.3%)    | 237 (66.4%)   |         | 901 (65.1%)   |         |
| Positive                      | 1498 (17.7%)    | 120 (33.6%)   |         | 484 (34.9%)   |         |

*PALN* para-aortic lymph node, *PLN* pelvic lymph node, *FIGO* International Federation of Gynecology and Obstetrics, *SCC* squamous cell carcinoma, *AC* adenocarcinoma, *SAC* adenosquamous carcinoma, *LVSI* lymphatic vessel space, *POAT* postoperative adjuvant treatment
1.1 Comparison of survival outcomes before matching overall stage IB1-IIA2 cervical cancer patients with or without PAL

KM analysis showed a statistically significant difference (86.8% vs 80.6%, \( p = 0.002 \)) in the 5-year DFS rate between the PALN unresected group (n = 8445) and the PALN resected group (n = 357), perhaps because of a baseline imbalance before matching. The tumor diameter (> 4 cm), histological type (adenocarcinoma, adenosquamous carcinoma), parametrial infiltration, positive LVSI, deep stromal invasion (> 1/2) and positive PLN in the PALN resected group were all higher than the PALN resected group before matching. Cox multivariate analysis showed that PALN resection was not an independent factor (\( p = 0.413 \)). The difference in the 5-year OS rates between the two groups was not statistically significant (91.5% vs. 89.2%, \( p = 0.429 \), \( p = 0.354 \)).

1.2 Comparison of survival outcomes after matching overall stage IB1-IIA2 cervical cancer patients with or without PAL

After 1:4 PSM matching, there was no significant difference in 5-year survival outcomes between the PALN unresected group (n = 1385) and the PALN resected group (n = 353) (OS 88.1% vs. 89.9%, \( p = 0.270 \), \( p = 0.344 \); DFS 82.3% vs. 81.0%, \( p = 0.666 \), \( p = 0.562 \)).

2. Different PLN metastasis states

2.1 Comparison of PALN survival outcomes before and after matching in patients with negative PLN metastasis of stage IB1-IIA2 cervical cancer with or without PAL (see Table 2 and Fig. 3)
Table 2
Clinicopathological characteristics of negative PLN metastasis in stage IB1-IIA2 cervical cancer patients with or without para-aortic lymphadenectomy

| Variables          | unmatched PALN unresected (n = 6947,%) | unmatched PALN Resected (n = 237,%) | P-value | matched PALN unresected (n = 948,%) | matched PALN Resected (n = 237,%) | P-value |
|--------------------|----------------------------------------|------------------------------------|---------|------------------------------------|------------------------------------|---------|
|                    |                                        |                                    |         |                                    |                                    |         |
| Age(years)         | 48.30 ± 9.773                          | 47.27 ± 9.262                      | 0.108   | 47.85 ± 9.597                      | 47.27 ± 9.262                      | 0.404   |
| FIGO stage         |                                        |                                    | 0.59    |                                    |                                    | 0.749   |
| IB1                | 4192(60.3%)                            | 148(62.4%)                         |         | 583(61.5%)                         | 148(62.4%)                         |         |
| IB2                | 652(9.4%)                              | 27(11.4%)                          |         | 129(13.6%)                         | 27(11.4%)                          |         |
| IIA1               | 1491(21.5%)                            | 48(20.3%)                          |         | 176(18.6%)                         | 48(20.3%)                          |         |
| IIA2               | 399(5.7%)                              | 9(3.8%)                            |         | 48(5.1%)                           | 9(3.8%)                            |         |
| IB                 | 111(1.6%)                              | 2(0.8%)                            |         | 4(0.4%)                            | 2(0.8%)                            |         |
| IIA                | 103(1.5%)                              | 3(1.3%)                            |         | 8(0.8%)                            | 3(1.3%)                            |         |
| Tumor size         |                                        |                                    | 0.7     |                                    |                                    | 0.304   |
| ≤ 4cm              | 5683(81.8%)                            | 196(82.7%)                         |         | 759(80.1%)                         | 196(82.7%)                         |         |
| > 4cm              | 1051(15.1%)                            | 36(15.2%)                          |         | 177(18.7%)                         | 36(15.2%)                          |         |
| Unknown            | 213(3.1%)                              | 5(2.1%)                            |         | 12(1.3%)                           | 5(2.1%)                            |         |
| Histological type  |                                        |                                    | < 0.001 |                                    |                                    | 0.798   |
| SCC                | 6255(90.0%)                            | 189(79.7%)                         |         | 761(80.3%)                         | 189(79.7%)                         |         |
| AC                 | 539(7.8%)                              | 39(16.5%)                          |         | 159(16.8%)                         | 39(16.5%)                          |         |
| SAC                | 153(2.2%)                              | 9(3.8%)                            |         | 28(3.0%)                           | 9(3.8%)                            |         |
| Parametrial        |                                        |                                    | 0.051   |                                    |                                    | 0.059   |
| Negative           | 6886(99.1%)                            | 232(97.9%)                         |         | 941(99.3%)                         | 232(97.9%)                         |         |
| Positive           | 61(0.9%)                               | 5(2.1%)                            |         | 7(0.7%)                            | 5(2.1%)                            |         |

PALN para-aortic lymph node, PLN pelvic lymph node, FIGO International Federation of Gynecology and Obstetrics, SCC squamous cell carcinoma, AC adenocarcinoma, SAC adenosquamous carcinoma, LVS/ lymphatic vessel space, POAT postoperative adjuvant treatment
In total, 7184 patients with stage IB1-IIA2 cervical cancer and negative PLN metastasis met the screening criteria. When PLN metastasis was negative, there was no significant difference in 5-year survival outcomes between the PALN unresected group (n = 6947) and the PALN resected group (n = 237) (OS 94.5% vs. 96.2%, *p* = 0.291, *p* = 0.195). DFS 90.6% vs. 88.7%, *p* = 0.371, *p* = 0.607). After 1:4 PSM matching, there was no statistically significant difference in 5-year survival outcomes between the PALN unresected group (n = 948) and the resected group (n = 237) (OS 94.5% vs. 96.2%, *p* = 0.292, *p* = 0.242; DFS 90.7% vs. 88.7%, *p* = 0.474, *p* = 0.607).

| Variables                  | unmatched | PALN | P-value | matched | PALN | P-value |
|----------------------------|-----------|------|---------|---------|------|---------|
|                            | unresected | Resected |         | unresected | Resected |         |
|                            | (n = 6947,%) | (n = 237,%) |         | (n = 948,%) | (n = 237,%) |         |
| **Vaginal margin**         |           |       |         | 0.142   | 0.668 |
| Negative                   | 6808(98.0%) | 229(96.6%) | 921(97.2%) | 229(96.6%) |
| Positive                   | 139(2.0%) | 8(3.4%) | 27(2.8%) | 8(3.4%) |
| **LVSI**                   |           |       | 0.603 | 0.836 |
| Negative                   | 6003(86.4%) | 202(85.2%) | 813(85.8%) | 202(85.2%) |
| Positive                   | 944(13.6%) | 35(14.8%) | 135(14.2%) | 35(14.8%) |
| **Cervical invasion**      |           |       | 0.601 | 0.525 |
| ≤ 1/2                      | 3067(44.1%) | 99(41.8%) | 431(45.5%) | 99(41.8%) |
| > 1/2                      | 3381(48.7%) | 123(51.9%) | 453(47.8%) | 123(51.9%) |
| Unknown                    | 499(7.2%) | 15(6.3%) | 64(6.8%) | 15(6.3%) |
| **POAT**                   |           |       | 0.354 | 0.914 |
| standard                   | 3486(50.2%) | 106(44.7%) | 422(44.5%) | 106(44.7%) |
| inadequate                 | 371(5.3%) | 16(6.8%) | 56(5.9%) | 16(6.8%) |
| over                       | 2927(42.1%) | 110(46.4%) | 444(46.8%) | 110(46.4%) |
| Unknown                    | 163(2.3%) | 5(2.1%) | 26(2.7%) | 5(2.1%) |

*PALN* para-aortic lymph node, *PLN* pelvic lymph node, *FIGO* International Federation of Gynecology and Obstetrics, *SCC* squamous cell carcinoma, *AC* adenocarcinoma, *SAC* adenosquamous carcinoma, *LVSI* lymphatic vessel space, *POAT* postoperative adjuvant treatment
2.2 Comparison of PALN survival outcomes before and after matching in patients with positive PLN metastasis of stage IB1-IIA2 cervical cancer with or without PAL (see Table 3 and Fig. 4)
Table 3
Clinicopathological characteristics of positive PLN metastasis in stage IB1-IIA2 cervical cancer patients with or without para-aortic lymphadenectomy

| Variables      | unmatched                   | matched                    |
|----------------|-----------------------------|----------------------------|
|                | PALN unresected             | PALN Resected              | P-value | PALN unresected | PALN Resected | P-value |
|                | (n = 1498,%)                | (n = 120,%)                |         | (n = 471,%)    | (n = 120,%)    |         |
| Age(years)     | 48.31 ± 9.573               | 48.77 ± 9.732              | 0.617   | 47.20 ± 9.649  | 47.75 ± 9.609 | 0.666   |
| FIGO stage     |                             |                            | 0.073   | 0.814          |              |         |
| IB1            | 587(39.2%)                  | 53(44.2%)                  |         | 215(45.6%)     | 53(44.2%)     |         |
| IB2            | 233(15.6%)                  | 25(20.8%)                  |         | 84(17.8%)      | 25(20.8%)     |         |
| IIA1           | 407(27.2%)                  | 23(19.2%)                  |         | 85(18.0%)      | 23(19.2%)     |         |
| IIA2           | 214(14.3%)                  | 19(15.8%)                  |         | 87(18.5%)      | 19(15.8%)     |         |
| IB             | 12(0.8%)                    | 0(0.0%)                    |         |                |               |         |
| IIA            | 45(3.0%)                    | 0(0.0%)                    |         |                |               |         |
| Tumor size     |                             |                            | 0.04    | 0.942          |              |         |
| ≤ 4cm          | 994(66.4%)                  | 76(63.3%)                  |         | 300(63.7%)     | 76(63.3%)     |         |
| >4cm           | 447(29.8%)                  | 44(36.7%)                  |         | 11(36.3%)      | 44(36.7%)     |         |
| Unknown        | 57(3.8%)                    | 0(0.0%)                    |         |                |               |         |
| Histological type |                       |                            | 0.152   | 0.077          |              |         |
| SCC            | 1332(88.9%)                 | 100(83.3%)                 |         | 426(90.4%)     | 100(83.3%)    |         |
| AC             | 117(7.8%)                   | 13(10.8%)                  |         | 27(5.7%)       | 13(10.8%)     |         |
| SAC            | 49(3.3%)                    | 7(5.8%)                    |         | 18(3.8%)       | 7(5.8%)       |         |
| Parametrical   |                             |                            | 0.003   | 0.846          |              |         |
| Negative       | 1421(94.9%)                 | 106(88.3%)                 |         | 419(89.0%)     | 106(88.3%)    |         |
| Positive       | 77(5.1%)                    | 14(11.7%)                  |         | 52(11.0%)      | 14(11.7%)     |         |

PALN para-aortic lymph node, PLN pelvic lymph node, FIGO International Federation of Gynecology and Obstetrics, SCC squamous cell carcinoma, AC adenocarcinoma, SAC adenosquamous carcinoma, LVS/ lymphatic vessel space, POAT postoperative adjuvant treatment
| Variables            | unmatched | P-value | matched | P-value |
|----------------------|-----------|---------|---------|---------|
|                      | PALN unresected (n = 1498,%) | PALN Resected (n = 120,%) |          |          |
| Vaginal margin       |           |         |         |         |
| Negative             | 1442(96.3%) | 112(93.3%) | 451(95.8%) | 112(93.3%) |
| Positive             | 56(3.7%)   | 8(6.7%)  | 20(4.2%) | 8(6.7%)  |
| LVSI                 |           |         |         |         |
| Negative             | 882(59.0%) | 60(50.0%) | 240(51.0%) | 60(50.0%) |
| Positive             | 614(41.0%) | 60(50.0%) | 231(49.0%) | 60(50.0%) |
| Cervical invasion   |           | 0.077   |         | 0.085   |
| ≤ 1/2                | 222(14.8%) | 9(7.5%)  | 72(15.3%) | 9(7.5%)  |
| > 1/2                | 1217(81.2%) | 107(89.2%) | 386(82.0%) | 107(89.2%) |
| Unknown              | 59(3.9%)   | 4(3.3%)  | 13(2.8%) | 4(3.3%)  |
| POAT                 |           |         |         |         |
| standard             | 1133(75.6%) | 101(84.2%) | 386(82.0%) | 101(84.2%) |
| inadequate           | 365(24.4%) | 19(15.8%) | 85(18.0%) | 19(15.8%) |

PALN para-aortic lymph node, PLN pelvic lymph node, FIGO International Federation of Gynecology and Obstetrics, SCC squamous cell carcinoma, AC adenocarcinoma, SAC adenosquamous carcinoma, LVSI lymphatic vessel space, POAT postoperative adjuvant treatment

In total, 1618 patients with stage IB1-IIA2 cervical cancer and positive PLN metastasis met the screening criteria. There was no statistically significant difference in 5-year survival outcomes between the PALN unresected group (n = 1498) and the PALN resected group (n = 120) (OS 77.6% vs. 75.9%, p = 0.953, p = 0.849; DFS 69.0% vs. 65.2%, p = 0.367, p = 0.593). After 1:4 PSM matching, there was no statistically significant difference in 5-year survival outcomes between the PALN unresected group (n = 471) and the resected group (n = 120) (OS 74.2% vs. 75.9%, p = 0.594, p = 0.414). DFS 67.6% vs. 65.2%, p = 0.733, p = 0.985).

Discussion
This study included 8802 patients with cervical cancer stage IB1-IIA2 who underwent ARH + PL, and 357 patients (4.06%) underwent PAL. In patients who underwent PAL, the rate of PALN isolated metastasis was 0.42% (1/237) when the PLN was negative. In contrast, when the PLN was positive, the rate of concurrent PALN metastasis was 30.00% (36/120). Our findings highlight the low risk of isolated PALN metastasis in patients with early operable cervical cancer. Notably, there was no statistically significant difference in 5-year survival outcomes between the ARH + PL and ARH + PL + PAL groups of patients with stage IB1-IIA2 cervical cancer.

This result is consistent with a retrospective study by Del Carmen et al.\(^3\), who reported no statistically significant difference in 3-year survival outcomes between patients receiving PLN + PALN resection and patients receiving PLN resection alone \((p = 0.69)\). Ayhan A et al.\(^5\) also suggested no statistically significant difference in 5-year survival outcomes between patients with early cervical cancer who underwent PAL and patients who did not undergo PAL.

Tsuruga et al.\(^4\) retrospectively analyzed 308 patients undergoing surgery for stage IB2, IIA2 or IIB cervical cancer. PAL failed to improve the oncological outcome. Among 30 patients with total iliac lymph node metastasis, the OS rate in the PAL group was relatively high \((p = 0.053)\), but the number of patients studied was small. Hackett TE et al.\(^6\) reported that all patients with stage IA2-IIA cervical cancer should undergo RH + PL without PAL, except for suspected metastasis of PLN or PALN. Our study found that when PLN metastasis was negative or positive, patients with stage IB1-IIA2 cervical cancer who received PAL did not show improved in 5-year survival outcomes. However, patients with positive PALN received adjuvant radiotherapy and chemotherapy, and it was not possible to evaluate whether PAL conferred a survival benefit. Lymph nodes are an important factor in the prognosis of patients, and the new FIGO staging in 2018\(^{13}\) classified patients with lymph nodes metastasis into stage IIIC. Whether PAL should be performed during the surgical treatment of cervical cancer of stage IB1-IIA2 under the new staging classification should be considered.

The rate of isolated PALN metastasis was low, which supports the recommendation that PLN-negative patients should not undergo this procedure because the associated complications may increase when lymph node resection is extended. Recent data suggested that sentinel lymph node biopsy may be useful for decreasing the need for PL in patients with early-stage cervical cancer\(^2\). Tsuruga et al.\(^4\) suggested that long-term complications in the PALN unrected group \((n = 119)\) were lower than the PALN resected group \((n = 135)\) in early cervical cancer patients who underwent RH + PL. The incidences of lymphedema, lymphocysts, and small intestinal or colonic obstruction in the two groups were 6.7%/14.1%, 1.7%/4.4%, and 16/15%, respectively. Finan MA et al.\(^7\) noted that PALN resection was the only independent predictor of surgical complications of early cervical cancer.

The present study analyzed the survival outcomes of PALN resection during abdominal surgery to eliminate the interference caused by different surgical approaches\(^{14}\). Notably, Liang et al.\(^{15}\) retrospectively found that laparoscopic surgery had more surgical complications than abdominal surgery. We found that the PALN resection rate of stage IB1-IIA2 cervical cancer patients was 27.27% (1104/4048)
following laparoscopic surgery in this database, which was significantly higher than the rate following abdominal surgery (4.06%, 357/8802). Therefore, abdominal surgery for cervical cancer could reduce PAL and complications. The omission of PAL in patients with pathologically negative PLN may be of great significance to the reduction of surgery-related complications.

The present study has the following limitations. Firstly, it was a retrospective study, and there may be selection bias. Why some patients did or did not undergo PAL cannot be determined. Secondly, due to space limitations, the comparison of complications between the PALN unresected group and the resected group of stage IB1-IIA2 cervical cancer patients were not included in this paper. In addition, this study focused on whether patients with ARH + PL treatment in stage IB1-IIA2 cervical cancer should undergo PAL, and could not be extrapolated to whether patients with staging procedure should undergo PAL. Finally, PAL was defined as PALN biopsy and low and high PALN dissection. Different PALN resection ranges may affect patient survival outcomes.

**Conclusions**

In summary, the results of this study suggest that the risk of PALN isolated metastasis is very low when the PLN is negative, and PAL is not recommended in surgical patients with stage IB1-IIA2 cervical cancer. When the PLN is positive, PAL did not significantly improve the prognosis, and PAL was associated with more complications and higher risks. Therefore, PAL should be carefully selected. This issue requires deeper prospective studies to verify.

**Abbreviations**

NCCN: National Comprehensive Cancer Network

RH: radical hysterectomy

PL: pelvic lymphadenectomy

PAL: para-aortic lymphadenectomy

PLN: pelvic lymph node

PALN: para-aortic lymph node

FIGO: International Federation of Gynecology and Obstetrics

LVSI: lymphovascular invasion

PSM: propensity score matching

**Declarations**
Ethics approval and consent to participate

The study has been accomplished following ethical principles according to the Declaration of Helsinki 1964. This retrospective study was approved by the Ethics Committee of the Nanfang Hospital of Southern Medical University (approval number NFEC-2017-135 and clinical trial number CHiCTR1800017778; International Clinical Trials Registry Platform Search Port, http://apps.who.int/trialsearch/), who deemed that written informed consent was not necessary due to the retrospective nature of the research and concealment of patient information.

Consent for publication

Not Applicable.

Availability of data and material

The datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request.

Competing interests

The authors declare that they have no competing interests to disclose.

Funding

The National Science and Technology Support Program of China (2014BAI05B03)

The Natural Science Foundation of Guangdong Province (2015A030311024)

The Science and Technology Plan of Guangzhou (158100075)

The above funding sources provided financial assistance that had an important role in data collection.

Authors’ Contributions

1. Chunlin Chen: Supervision, Conceptualization, Project administration, Funding acquisition.
2. Hui Duan: Methodology, Data Curation, Writing-Original Draft, Writing-Review & Editing.
3. Wenling Zhang: Investigation, Writing-Original Draft, Writing-Review & Editing.
4. Hongwei Zhao: Investigation, Data Curation, Resources.
5. Li Wang: Investigation, Resources.
6. Shan Kang: Investigation, Resources.
7. Lihong Lin: Investigation, Resources.
8. Weidong Zhao: Investigation, Resources.
9. Yan Ni: Investigation, Resources.
10. Donglin Li: Investigation, Resources.
11. Jiaming Chen:
12. Huijian Fan:
13. Xiaolin Chen:
14. Xiaonong Bin: Formal analysis.
15. Jinghe Lang: Supervision, Conceptualization.
16. Ping Liu: Supervision, Conceptualization, Project administration.

All authors read and approved the final manuscript.

Acknowledgements

We are grateful to Min Hao (The second hospital of ShanXi medical university), Bin Ling (China-Japan Friendship Hospital), Lixin Sun (Shanxi Cancer Hospital), Jihong Liu and Lizhi Liang (Sun Yatsen University Cancer Center), Yu Guo (Anyang Tumor Hospital), Wentong Liang and Anwei Lu (Guizhou Provincial People`s Hospital), Jianxin Guo (Daping Hospital, The Third Military Medical University), Shaoguang Wang (The Affiliated Yantai Yuhuangding Hospital of Qingdao University), Xuemei Zhan and Mingwei Li (Jiangmen Central Hospital), Weifeng Zhang (Ningbo Women & Children's Hospital), Peiyan Du (The Affiliated Cancer Hospital and Institute of Guangzhou Medical University), Ziyu Fang (Liuzhou workers' hospital), Rui Yang (Shenzhen hospital of Peking University), Long Chen (Qingdao Municipal Hospital), Encheng Dai and Ruilei Liu (Linyi People's Hospital), Yuanli He and Mubiao Liu (Zhujiang Hospital, Southern Medical University), Jilong Yao and Zhihua Liu (Shenzhen Maternity & Child Health Hospital), Xueqin Wang (The Fifth Affiliated Hospital of Southern Medical University), Yan Xu (Guangzhou Pan Yu Central Hospital), Ben Ma (Guangzhou First People's Hospital), Zhonghai Wang (Shenzhen Nanshan People's Hospital), Lin Zhu (The Second Hospital of Shandong University), Hongxin Pan (The Third Affiliated Hospital of Shenzhen University), Qianyong Zhu (No.153. Center Hospital of Liberation Army /Hospital No.988 of the Chinese People's Liberation Army Joint Support Force), Dingyuan Zeng and Zhong Lin (Maternal and Child Health Care Hospital of Liuzhou) and Xiaohong Wang (Laiwu People's Hospital/Jinan City People's Hospital) and Bin Zhu (The Affiliated Yiwu Women and Children Hospital of Hangzhou Medical College) for their contribution in data collection.

References
1. Wild CP, Weiderpass E, Stewart BW, editors (2020). World Cancer Report: Cancer Research for Cancer Prevention. Lyon, France: International Agency for Research on Cancer. Available from: http://publications.iarc.fr/586. Licence: CC BY-NC-ND 3.0 IGO.

2. Koh WJ, Abu-Rustum NR, Bean S, et al. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019. 17(1): 64–84.

3. Del CMG, Pareja R, Melamed A, et al. Isolated para-aortic lymph node metastasis in FIGO stage IA2-IB2 carcinoma of the cervix: Revisiting the role of surgical assessment. Gynecol Oncol. 2018. 150(3): 406–411.

4. Tsuruga T, Fujimoto A, Kawana K, et al. Radical hysterectomy with or without para-aortic lymphadenectomy for patients with stage IB2, IIA2, and IIB cervical cancer: outcomes for a series of 308 patients. Int J Clin Oncol. 2016. 21(2): 359–366.

5. Ayhan A, Tuncer ZS, Ayhan A. Effect of paraaortic lymphadenectomy on 5-year survival in early stage cervical cancer. Aust N Z J Obstet Gynaecol. 1990. 30(4): 378 – 80.

6. Hackett TE, Olt G, Sorosky JI, Podczaski E, Harrison TA, Mortel R. Surgical predictors of para-aortic metastases in early-stage cervical carcinoma. Gynecol Oncol. 1995. 59(1): 15 – 9.

7. Finan MA, Hoffman MS, Chambers R, et al. Body mass predicts the survival of patients with new International Federation of Gynecology and Obstetrics Stage IB1 and IB2 cervical carcinoma treated with radical hysterectomy. Cancer. 1998. 83(1): 98–102.

8. Zhang W, Chen C, Liu P, et al. Impact of pelvic MRI in routine clinical practice on staging of IB1-IIA2 cervical cancer. Cancer Manag Res. 2019. 11: 3603–3609.

9. Chen C, Liu P, Ni Y, et al. Laparoscopic versus abdominal radical hysterectomy for stage IB1 cervical cancer patients with tumor size ≤ 2 cm: a case-matched control study. Int J Clin Oncol. 2020. 25(5): 937–947.

10. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009. 105(2): 103-4.

11. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol. 1999. 73(2): 177 – 83.

12. NCCN. Cervical Cancer, Version 1.2021, NCCN Clinical Practice Guidelines in Oncology.

13. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet. 2018. 143 Suppl 2: 22–36.

14. Ramirez PT, Frumovitz M, Pareja R, et al. Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. N Engl J Med. 2018. 379(20): 1895–1904.

15. Liang C, Liu P, Cui Z, et al. Effect of laparoscopic versus abdominal radical hysterectomy on major surgical complications in women with stage IA-IIIB cervical cancer in China, 2004–2015. Gynecol Oncol. 2020. 156(1): 115–123.
Figures

Figure 1

Data screening process PLN pelvic lymph node, PALN para-aortic lymph node
Figure 2

Survival curves of overall stage IB1 and IIA2 cervical cancer patients before and after matching *Before matching, panels A and B; after matching, panels C and D; PALN para-aortic lymph node.
Figure 3

Survival curves of negative PLN metastasis in stage IB1 and IIA2 cervical cancer patients before and after matching *Negative PLN: before matching, panels A and B; after matching, panels C and D; PALN para-aortic lymph node; PLN pelvic lymph node
Survival curves of positive PLN metastasis in stage IB1 and IIA2 cervical cancer patients before and after matching.

*Positive PLN: before matching, panels A and B; after matching, panels C and D; PALN para-aortic lymph node; PLN pelvic lymph node.